NSNan Song

Nan Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nan Song has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Gening Jiang

    Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

    3 shared publications
  • Peng Zhang

    Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China

    3 shared publications
  • Xinsheng Zhu

    Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China

    3 shared publications
  • Yong Xu

    Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

    3 shared publications
  • Jing Zhang

    Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

    2 shared publications
  • Lu Han

    Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China

    2 shared publications

Latest Publications

  • Immunoprotective Multifunctional Nanofiber–Hydrogel Janus Membranes for Advanced Ectopic Cartilage Regeneration

    by Yaqiang Li, Zhao An, Xiaowei Xun, Jinpeng Wang, Xiaogang Liu, Yong Xu, Siqiang Zheng, Xiang Fei, Nan Song

  • Open Access

    Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial

    by Shuyu Ji, Zhenxin Sheng, Dongliang Bian, Minwei Bao, Kaiqi Jin, Wentian Zhang, Xinsheng Zhu, Fenghuan Sun, Haoran Xia, Han Zhang, et al.

    This study aimed to evaluate the efficacy and safety of camrelizumab, an anti-PD-1 antibody, combined with either chemotherapy or apatinib, a VEGFR-2 inhibitor, as neoadjuvant treatment for stage IIA-IIIA NSCLC. This prospective, multicenter, dual-arm, non-randomized phase II trial enrolled participants from four hospitals in China between September 2020 and March 2022. Patients received 2-4 cycles of neoadjuvant treatment followed by surgery. Arm-AR (n = 28) included patients treated with camrelizumab (200 mg every 3 weeks) plus platinum-based chemotherapy, regardless of PD-L1 status. Arm-BR (n = 10) included PD-L1-positive patients treated with camrelizumab (200 mg every 3 weeks) plus apatinib (250 mg daily). The primary endpoint was the major pathological response (MPR) rate. Secondary endpoints included pathological complete response (pCR) rate, objective response rate (ORR), disease control rate (DCR), event-free survival (EFS), overall survival (OS), and safety profiles. In the ITT population, MPR rates were 25.0% (95% CI 10.7-44.9) in arm-AR and 60.0% (95% CI 26.2-87.8) in arm-BR. The 24-month EFS rates were 53.6% and 70.0%, respectively, after a median follow-up of 30.5 months. Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 25% of arm-AR patients and 10% of arm-BR patients. Camrelizumab combined with platinum-based chemotherapy demonstrated promising efficacy and tolerability for resectable IIA-IIIA NSCLC, regardless of PD-L1 status. In PD-L1-positive patients, camrelizumab plus apatinib showed improved safety and effectiveness, highlighting a potential treatment option for this subgroup. NCT04379739, initiated on July 26, 2020.


  • Injectable and self-healing sulfated hyaluronic acid/gelatin hydrogel as dual drug delivery system for circumferential tracheal repair

    by YaYan Yang, Xinsheng Zhu, Xuezhe Liu, Kai Chen, Yunping Hu, Pei Liu, Yong Xu, Xiufeng Xiao, Xiaogang Liu, Nan Song, et al.


  • Significance of spread through air spaces in small cell lung cancer

    by Lu Han, Zhida Huang, Jing Zhang, Yan Chen, Jue Wang, Yicheng Xiong, Wangchao Yao, Likun Hou, Liping Zhang, Huansha Yu, et al.

    Purpose Tumor spread through air space (STAS) is a novel pattern of invasion related to poor prognosis in non-small cell cancer (NSCLC). Nevertheless, little is known about the role of STAS in small cell lung cancer (SCLC). We sought to determine whether STAS has a significant effect on recurrence among SCLC patients. Methods We collected clinical and follow-up information from 181 resected stage I–III SCLC patients and compared overall survival (OS) and disease-free survival (DFS) between the patients with or without STAS using the Kaplan‒Meier method. To explore the effect of STAS on recurrence, a competing-risk analysis was conducted. Results Among 181 SCLC patients, STAS was observed in 56 (30.94%) patients, and 125 (69.06%) patients did not have STAS. Furthermore, 33 (18.23%) patients had recurrence, including 12 patients with brain metastases. Patients with STAS had worse DFS. The cumulative incidence of any recurrence was higher in patients with STAS than in those without STAS. Univariate and multivariate competing-risk regression analyses revealed that sublobar resection and STAS were independent risk factors for SCLC recurrence (p = 0.009 and p = 0.029 for multivariate analysis, respectively). Conclusion SCLC patients with STAS have worse DFS than SCLC patients without STAS. STAS is an independent prognostic factor in SCLC patients.


  • Open Access

    Single-cell RNA sequencing analysis to explore immune cell heterogeneity and novel biomarkers for the prognosis of lung adenocarcinoma

    by Yong Xu, Yao Wang, Leilei Liang, Nan Song

    Background: Single-cell RNA sequencing is necessary to understand tumor heterogeneity, and the cell type heterogeneity of lung adenocarcinoma (LUAD) has not been fully studied.Method: We first reduced the dimensionality of the GSE149655 single-cell data. Then, we statistically analysed the subpopulations obtained by cell annotation to find the subpopulations highly enriched in tumor tissues. Monocle was used to predict the development trajectory of five subpopulations; beam was used to find the regulatory genes of five branches; qval was used to screen the key genes; and cellchart was used to analyse cell communication. Next, we used the differentially expressed genes of TCGA-LUAD to screen for overlapping genes and established a prognostic risk model through univariate and multivariate analyses. To identify the independence of the model in clinical application, univariate and multivariate Cox regression were used to analyse the relevant HR, 95% CI of HR and p value. Finally, the novel biomarker genes were verified by qPCR and immunohistochemistry.Results: The single-cell dataset GSE149655 was subjected to quality control, filtration and dimensionality reduction. Finally, 23 subpopulations were screened, and 11-cell subgroups were annotated in 23 subpopulations. Through the statistical analysis of 11 subgroups, five important subgroups were selected, including lung epithelial cells, macrophages, neuroendocrine cells, secret cells and T cells. From the analysis of cell trajectory and cell communication, it is found that the interaction of five subpopulations is very complex and that the communication between them is dense. We believe that these five subpopulations play a very important role in the occurrence and development of LUAD. Downloading the TCGA data, we screened the marker genes of these five subpopulations, which are also the differentially expressed genes in tumorigenesis, with a total of 462 genes, and constructed 10 gene prognostic risk models based on related genes. The 10-gene signature has strong robustness and can achieve stable prediction efficiency in datasets from different platforms. Two new molecular markers related to LUAD, HLA-DRB5 and CCDC50, were verified by qPCR and immunohistochemistry. The results showed that HLA-DRB5 expression was negatively correlated with the risk of LUAD, and CCDC50 expression was positively correlated with the risk of LUAD.Conclusion: Therefore, we identified a prognostic risk model including CCL20, CP, HLA-DRB5, RHOV, CYP4B1, BASP1, ACSL4, GNG7, CCDC50 and SPATS2 as risk biomarkers and verified their predictive value for the prognosis of LUAD, which could serve as a new therapeutic target.


  • Open Access

    Surgical Options for Resectable Lung Adenosquamous Carcinoma: A Propensity Score-Matched Analysis

    by Shuncang Zhu, Tao Ge, Yicheng Xiong, Jing Zhang, Di Zhu, Liangdong Sun, Nan Song, Peng Zhang

    Background: Surgery is the primary treatment option for Lung adenosquamous carcinoma (ASC) patients. However, no study compares the benefits of lobectomy and sublobar resection in ASC patients.Methods: A total of 1379 patients in the Surveillance, epidemiology, and End Results (SEER) database and 466 patients in Shanghai Pulmonary Hospital (SPH) were enrolled. Survival benefits were evaluated after possible confounders were eliminated by propensity score matching (PSM).Results: After 1:3 PSM, 463 SEER database patients and 244 SPH patients were enrolled. Lobectomy was associated with better overall survival (OS) and disease-free survival (DFS) than sublobar resection for ASC patients (5-year OS of SEER: 46.9% vs. 33.3%, P =0.017; 5-year OS of SPH: 35.0% vs. 16.4%, P =0.002; 5-year DFS of SPH: 29.5% vs. 14.8%, P =0.002). Similar results were observed in stage I patients. Univariate and multivariate Cox regression analyses showed that sublobar resection was an adverse prognostic factor independently (SEER: HR: 1.40, 95%CI: 1.08-1.81, P =0.012; SPH: HR: 1.73, 95%CI: 1.11-2.70, P =0.015). Subgroup analysis showed that all of the ASC patient subtypes tended to benefit more from lobectomy than sublobar resection.Conclusions: Lobectomy remains the primary option for ASC patients compared to sublobar resection, including stage I.


  • Bevacizumab‐Laden Nanofibers Simulating an Antiangiogenic Niche to Improve the Submuscular Stability of Stem Cell Engineered Cartilage

    by Xinsheng Zhu, Yong Xu, Xiaoxiong Xu, Junjie Zhu, Linsong Chen, Yawen Xu, Yang Yang, Nan Song

    Bone marrow stem cells (BMSCs) engineered cartilage (BEC) is prone to endochondral ossification in a submuscular environment due to the process of vascular infiltration, which limits its application in repairing tracheal cartilage defects. Bevacizumab, an antitumor drug with pronounced antiangiogenic activity, is successfully laden into a poly(L‐lactide‐co‐caprolactone) system to prepare bevacizumab‐laden nanofiber (BevNF) characterized by 5% and 10% bevacizumab concentrations. The in vitro results reveal that a sustained release of bevacizumab can be realized from BevNF, exhibiting inhibitive cytotoxicity toward human umbilical vein endothelial cells whereas non‐cytotoxicity toward BMSCs‐induced chondrocytes. A model is also established by encapsulating BEC within BevNF, aiming to realize an antiangiogenic niche under conditions of sustained and localized release of bevacizumab to inhibit the process of vascular invasion, resulting in the eventual stabilization of the cartilaginous phenotype and promotion of the process of cartilage maturation in the submuscular environment. These results also confirm that the chondrogenesis stability of BEC increases with an increase in the bevacizumab concentration, and 10% BevNF is sufficient to protect BEC from vascularization. This demonstrates that the use of BevNF can potentially help develop an effective strategy for regulating the submuscular stability of BEC to repair the defects formed in tracheal cartilage.


  • Open Access

    Left sleeve pneumonectomy via uniportal video‐assisted thoracoscopic approach

    by Jianqiao Cai, Nan Song, Lei Jiang

    Left sleeve pneumonectomy is a rarer intervention compared with right sleeve pneumonectomy. It is a challenging surgical therapeutic strategy even when performed through open thoracotomy. Here, we report a case of uniportal video‐assisted thoracoscopic surgery (VATS) left sleeve pneumonectomy in a patient with non‐small cell lung cancer. The tumor, located at the opening of left upper lobe bronchus, submucosally invaded the orifice of lower lobe extending upward to 4 to 5 cartilage rings of the left main bronchus and to the level of the carina. Left sleeve pneumonectomy and airway reconstruction was performed through video‐assisted thoracoscopic completely with an incision of 4 cm. The total operative time was 220 minutes and the estimated intraoperative blood loss was 300 mL. Chylothorax occurred after surgery, which was well handled, and no other severe complication was observed. Three months after the surgery, the follow‐up bronchoscopy revealed good healing of the anastomosis. No signal of tumor recurrence was observed by follow‐up examination 1 year after the surgery. To our knowledge, this is the first reported uniportal VATS left sleeve pneumonectomy in the world. It was indicated that uniportal VATS might be a feasible approach for left sleeve pneumonectomy, with less surgical trauma compared with other approaches.